Navigation Links
Dalton and AdeTherapeutics Enter Into a Manufacturing Services Agreement
Date:1/6/2011

TORONTO, Jan. 6, 2011 /PRNewswire/ -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Clinical Manufacturing Services Agreement with AdeTherapeutics (a day' therapeutics), Inc., a specialty pharma company based in Saskatoon, Saskatchewan, focused on providing quality therapeutic options in inflammation and acute care medicine. Dalton will provide aseptic fill/finish services under cGMP, for ADE's sterile anti-adhesion (scar tissue reduction) product.

"Our Establishment License from Health Canada, combined with our expert capabilities in analytical services and aseptic manufacturing, solidified the manufacturing agreement," said Peter Pekos, President and CEO. "Dalton is pleased to add this strategic relationship to our growing list of innovative pharmaceutical clients.  We are thrilled to be working with AdeTherapeutics and look forward to rapidly moving their product through their key milestones," continued Pekos.

Sanj Singh, President and Chief Executive Officer of AdeTherapeutics remarked, "The partnership with Dalton is a key part of AdeTherapeutics capital efficient virtual drug development model where we work with expert service providers from all over the globe to rapidly bring our novel therapeutics and diagnostics forward benefiting the healthcare community with safe, reliable and cost-effective treatment choices. We are excited about the opportunity to partner with a company whose client focus and commitment to quality match our own. Sharing these values with partners like Dalton is vital to our ability to provide products which fulfill the therapeutic needs of physicians and their patients. Surgeries are expected to double in the next five years and with no established standard of care, we are optimistic that our lead anti-adhesion candidate can solve this high unmet medical need."

About Dalton


'/>"/>

SOURCE Dalton Pharma Services
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dalton Pharma Services Announces Successful Completion of Health Canada Inspection
2. Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
3. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
4. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
5. UAS Laboratories Enters Into Agreement to Launch New Probiotic Product at Expo West
6. HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy
7. Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinsons Disease Target LRRK2
8. Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals
9. Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share
10. Worlds smallest battery created at CINT nanotechnology center
11. Shrink Nanotechnologies Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... /CNW/ - Softchoice, a leading North American IT solutions and managed ... of two Cisco® Partner Summit Country awards. ... Security Partner of the Year for Canada ... in Montreal . "We ... awards at this year,s conference," said David MacDonald , ...
(Date:5/1/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... Care Conference in Boston, Massachusetts . ... 2015, at 3:30 PM Eastern Time, and can be accessed ...
(Date:4/30/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... commenced an underwritten public offering of its common stock.  ... 30-day option to purchase up to an additional 15 ... the public offering. The offering is subject to market ... whether or when the offering may be completed, or ...
(Date:4/30/2015)... April 30, 2015  The Paul G. Allen Family ... (ADI) grants to six groups of researchers with projects ... roadblocks in neuroscience: growing mature human brain cells in ... of $7.5 million over three years.  ... research is especially significant because the field of neuronal ...
Breaking Biology Technology:Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5
... Massachusetts and LAUSANNE, Switzerland, August 6 /PRNewswire/,-- Curis, ... development company focused on,developing proprietary targeted medicines for ... companies with a focus on the development of,prescription ... that they,have entered into a worldwide, exclusive license ...
... China, Aug. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced the appointment of Mr.,William Wei Lee as an ... effective August 4, 2009. Mr. Jiang Qi-Feng resigned from ...
... 6 Interleukin Genetics, Inc. (NYSE Amex: ... conference call and webcast on Thursday, August 13, 2009, at 4:30 ... financial results. , , To access the live ... replay access of the teleconference will be available on the Investors ...
Cached Biology Technology:Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 2Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 3Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 4Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 5Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 6China Sky One Medical, Inc. Appoints New Independent Director 2China Sky One Medical, Inc. Appoints New Independent Director 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Northwest National Laboratory scientists have used electrostatic attraction ... carbon nanotubes. , This configuration can accommodate ... monitoring to infectious-agent detection, said Yuehe Lin, who ... campus' W.R. Wiley Environmental Molecular Sciences Laboratory. ...
... a vaccine designed to fight avian influenza will begin this ... is part of a multicenter trial that will test a ... whether the vaccine still triggers a strong immune response at ... the National Institute of Allergy and Infectious Diseases of the ...
... online today in the journal Nature Methods, researchers at ... powerful new tool that will facilitate genetic research and ... genetic disease. , The researchers have combined several ... lentiviral vector ?a gene delivery system partly derived from ...
Cached Biology News:A biosensor layered like lasagna 2Duke to test bird flu vaccine dosing 2Swiss researchers develop all-in-one remote control gene expression tool 2